Iliana Djagova is partner in the Corporate/M&A team of Walder Wyss. She has extensive experience advising on complex domestic and cross-border M&A transactions, growth equity financings and late-stage investments as well as capital market and public takeover transactions. She regularly acts for strategic and financial investors, including private equity firms, on both the buy-side and sell-side. Iliana also advises companies and shareholders throughout all stages of their lifecycle, with a particular focus on growth-stage and exit transactions. In addition, she counsels private and listed companies, as well as their shareholders, on corporate governance and general corporate and commercial law matters.

Prior to joining Walder Wyss in 2023, Iliana spent eight years at another leading Swiss law firm, advising on high-profile M&A and private equity transactions. In 2015/16 she further broadened her international experience at Willkie Farr & Gallagher LLP in New York, USA.

Iliana studied law at the University of Geneva and Zurich (lic. iur., 2010) and the University of California, Berkeley (LL.M., 2015). She was admitted to the Zurich Bar in 2013 and to the New York Bar in 2018.

Iliana's professional languages are German and English. She also speaks Bulgarian and French.

Significant Accomplishments

Biotech Company CRISPR Therapeutics (NASDAQ) issued USD 600M Convertible Notes

SIS Medical AG - Investment by Claret Capital Partners

Beförderungen bei Walder Wyss

Tender offer for u-blox successfully completed

Swiss MedTech company Distalmotion SA closes USD 150m Series G Financing Round

IFLR 1000 Rankings 2025 - Walder Wyss as a top-performing law firm ranked

Corient acquires Stonehage Fleming and Stanhope Capital

Public Tender Offer for SIX-listed u-blox

SoftwareOne successfully completes its tender offer for Crayon

Walder Wyss advised Novo Holdings on the acquisition of Catalent

SoftwareOne to launch tender offer for all outstanding Crayon shares

Alentis Therapeutics Raises USD 181.4m in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

Boehringer Ingelheim acquires veterinary therapeutic vaccines developer Saiba Animal Health

Swixx Biopharma acquires Biopas to enter Latin America

SOPHiA GENETICS SA closed secured term loan financing

Walder Wyss advised CRISPR Therapeutics (NASDAQ) on USD 280 Million Equity Issuance

Walder Wyss advised Nasdaq listed Altamira Therapeutics in its sale of majority stake in Altamira Medica

Switzerland: A Corporate/M&A Overview
Kommentar zu Art. 659-659b und 783 OR betr. eigene Aktien und Stammanteile (Online Aktualisierung)
Equity Finance 2025 - Chapter Switzerland